Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-01-03
2006-01-03
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
06982321
ABSTRACT:
An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequence for producing the altered antibody may be produced by site-directed mutagenesis using long oligonucleotides or using gene synthesis.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5225539 (1993-07-01), Winter
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5846534 (1998-12-01), Waldmann et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6548640 (2003-04-01), Winter
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 0125023 (1984-11-01), None
patent: 0173494 (1986-03-01), None
patent: 0183964 (1986-06-01), None
patent: 0184187 (1986-06-01), None
patent: 0239400 (1987-09-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/09966 (1992-07-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Panka et al (Proc Natl Acad Sci USA vol. 85 3080-3084 May 1988.
Amit et al Science vol. 233 747-753 1986.
Riechmann et al (Nature 332:323-327, Mar. 24, 1988.
Cruse et al (Illustrated Dictionary of Immunology, CRC Press, 1995, p. 186.
Sonnier et al (The New England journal of Medicine 309:590-594, 1983.
Kabat et al (Sequences of protein of Immunological interest, US department of health, 1997, pp. 41 and 45.
Bentley, G.A., “Three-Dimensional Structure of an Idotope-Anti-idotope Complex,”Nature348:254-257 (1990).
Bhat, T.N. et al., “Small Rearrangements in Structures of Fv and Fab Fragments of Antibody D1.3 on Antigen Binding,”Nature347(6292):483-485 (1990).
Boulianne, et al., “Production of Functional Chimaeric Mouse/Human Antibody,”Nature312:643-646 (1984).
Bruggemann, et al., “Immunoglobulin V Region Variants in Hybridoma Cells I. Isolation of a Variant with Altered Idiotypic and Antigen Binding Specificity,”The EMBO Journal1(5):629-634 (1982).
Carter, et al., “Improved oligonucleotide site-directed mutagenesis using M13 vectors,”Nucleic Acids Res. 13:4431-4443 (1985).
Chen, P., et al., “Possible Involvement of Human D. Minigenes in the First Complementarity-Determining Region of k Light Chains,”Proceedings of the National Academy of Sciences of the U.S.A. 82:2125-2127 (Apr. 1985).
Chothia et al., “The Predicted Structure of Immunoglobulin D1.3 and its Comparison with the Crystal Structure,”Science233:755-758 (1986).
Chothia et al.,J. Mol. Biol.196:901-917 (1987).
Chothia, C., et al., “Conformations of Immunoglobulin Hypervariable Regions,”Nature342:877-883 (1989).
Colman et al.,Nature326:358-363 (1987).
Davies, D.R., et al., “Antibody-Antigen Complexes,”J. Biol. Chem. 263(22):10541-10544 (1988).
Dildrop et al., “Immunoglobulin V region variants in hybridoma cells. II. Recombination between V genes,”EMBO J. 1:635-640.
Duncan, A.R., et al., “the Binding Site for Clq on IgG,”Nature, 332(6166):738-740 (1988).
Emery and Adair, “Humanised monoclonal antibodies for therapeutic applications,”Exp. Opin. Invest. Drugs3:241-251 (1994).
Epp et al.,Eur. J. Biochem45:513-524 (1974).
Fersht, et al.,Nature314:235-238 (1985).
Foote and Winter, “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol. 224:487-499 (1992).
Graziano et al., “Construction and characterization of a humanized anti-γ-immunoglobulin receptor type I (FcγRI) monoclonal antibody,”J. Immunol. 155:4996-5002 (1995).
Groves, et al.,Hybridoma6(1):71-78 (1987).
Güssow and Seemann, “Humanization of monoclonal antibodies,”Methods on Enzymology, Acad. Press203(5):99-121.
Hale, et al.,Laneet1394-1399 (1988).
Herron, J.N., et al., “Three-Dimensional Structure of a Fluorescein-Fab Complex . . . ,”Proteins: Structure, Function, and Genetics5:271-280 (1989).
Hodgson, “Protein Design: Rules, Empireism, and Nature,”Biotechnology8:1245-1247 (1990).
Hudson et al., “Immunoglobulin Chain Recombination Among Antidigoxin Antibodies . . . ,”J Immunol. 139:2715-2723 (1987).
Jaffers et al.,Transplantation41:572-578 (1986).
Jones, P., et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature321:522-525 (May 1986).
Julius, M.A., et al., “The Structural Basis of Antigenic Determinants on Vk21 Light-Chains,”Mol. Immunol. 18:1-9 (1981).
Kabat, et al., “Advances in Protein Chemistry,”Acadamic Press32:2-75 (1978).
Kabat, et al., “Evidence Supporting Somatic Assembly of the DNA Segments (Minigenes), Coding for the Framework, and Complementarity-Determining Segments of Immunoglobulin Variable Regions,”J. Exp. Med.149:1299-1313 (1979).
Kabat, et al., “Sequences of Proteins of Immunological Interest,” pp. i-xx (1983).
Kettleborough, C.A., et al., “Humanization of a Mouse Monoclonal Antibody by CDR Grafting,”Protein Engineering4(7):772-783 (1991).
Lesk and Chothia, “Evolution of proteins formed by β-sheets: II. The core of the Immunoglobulin domains,”J. Mol. Biol. 160:325-342 (1982).
Marks, J.D., et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,”Biotechnology(in press).
Morrison et al., “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains,”Natl. Acad. Sci. USA 81:6851-6855 (1984).
Morrison, S.L.,Science229:1202-1207 (1985).
Munro, Alan, “Uses of chimaeric antibodies,”Nature312:597 (1984).
Neuberger et al.,Nature314:268-270 (1985).
Neuberger, “Making novel antibodies by expressing transfected immunoglobulin genes,”Trends in Biochem. Sci. 347-349 (1985).
Neuberger, “Novel antibodies by DNA transfection,”In Advances in Immunopharmacology 3, Proc. of Third Int'l Conf. Immunopharmacology, Florence, Italy(1985).
Nose, et al., “Biological Significance of Carbohydrate Chains on Monoclonal Antibodies,”Proc. Natl. Acad. Sci. USA 80:6632-6636 (1983).
Ochi, et al., “Functional Immunoglobulin M Production After Transfection of Cloned Immunoglobulin Heavy and Light Chain Genes Into Lymphoid Cells,”Natl. Acad. Sci. USA 80:6351-6355 (1983).
Oi, et al., “Immunoglobulin Gene Expression in Transformed Lymphoid Cells,”Proc. Natl. Acad. Sci. USA 80:825-829 (1983).
Old, R.W., et al., “Principles of Gene Manipulation,”Blackwell Scientific Pub. 99-101 (1980).
Padlan et al.,Cold Springs Harbor Symp. Quant. Biol. 41:627-637 (1976).
Padlan et al.,PNASUSA 86:5938-5942 (1989).
Painter, R.G., et al., “Contribution of Heavy and Light Chains of Rabbit Immunoglobulin G to Antibody Activity,”Biochemistry11(8):1327-1337 (1972).
Rechavi, et al., “Organization and Evolution of Immunoglobulin VH Gene Subgroups,”Proc. Natl. Acad. Sci. USA 82:4405-4409 (1982).
Rees and de la Paz, “Investigating antibody specificity using computer graphics and protein engineering,”Trends in Biochem. Sci. 11: 144-148 (1986).
Riechman Declaration from Opposition of European Patent No. 451,216B1.
Riechman and Winter, “Recombinant Antibodies Advances in the Applications of Monoclonal Antibodies in the Clinical Oncology,”Abstract for Meeting at Wolfson Institute(May 1987).
Sahagan, et al., “A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen,”J. Immunol. 137(3):1066-1074 (1986).
Sheriff, S., et al., “Three-Dimensional Structure of an Antibody-Antigen Complex,”Proc. Natl. Acad. Sci. USA 84:8075-8079 (1977).
Sims e
BTG International Limited
Gyure Barbara A.
Helms Larry R.
Medical Research Council
Palmer & Dodge LLP
LandOfFree
Altered antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Altered antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Altered antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3578417